WO2004024939A3 - Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof - Google Patents

Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof Download PDF

Info

Publication number
WO2004024939A3
WO2004024939A3 PCT/US2003/028931 US0328931W WO2004024939A3 WO 2004024939 A3 WO2004024939 A3 WO 2004024939A3 US 0328931 W US0328931 W US 0328931W WO 2004024939 A3 WO2004024939 A3 WO 2004024939A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
certain embodiments
activated receptor
peroxisome proliferator
compounds
Prior art date
Application number
PCT/US2003/028931
Other languages
French (fr)
Other versions
WO2004024939A2 (en
Inventor
Alan P Kozikowski
Robert I Glazer
Pavel Petukhov
Zhi-Liang Wei
Original Assignee
Univ Georgetown
Alan P Kozikowski
Robert I Glazer
Pavel Petukhov
Zhi-Liang Wei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Alan P Kozikowski, Robert I Glazer, Pavel Petukhov, Zhi-Liang Wei filed Critical Univ Georgetown
Priority to AU2003278814A priority Critical patent/AU2003278814A1/en
Publication of WO2004024939A2 publication Critical patent/WO2004024939A2/en
Publication of WO2004024939A3 publication Critical patent/WO2004024939A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

One aspect of the present invention relates to compounds that are active at a peroxisome proliferator-activated receptor (PPAR). In certain embodiments, the compound has a isoxazole or indole core. Another aspect of the present invention relates to a method of treating a mammal afflicted with cancer or non-insulin-dependent (type II) diabetes by administering a therapeutic amount of the compounds of the invention. In certain embodiments, the invention relates to a method of treating prostrate, stomach, or breast cancer. Another aspect of the invention relates to a method of identifying ligands active at a PPAR subtype using X-ray structural information. In certain embodiments, the method of identifying the ligand comprises using molecular modeling approaches including: in silico screening of chemical databases, de novo/rational drug design in which the ligand will be created computationally, and/or in silico screening of virtual combinatorial libraries.
PCT/US2003/028931 2002-09-13 2003-09-12 Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof WO2004024939A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003278814A AU2003278814A1 (en) 2002-09-13 2003-09-12 Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41067702P 2002-09-13 2002-09-13
US60/410,677 2002-09-13

Publications (2)

Publication Number Publication Date
WO2004024939A2 WO2004024939A2 (en) 2004-03-25
WO2004024939A3 true WO2004024939A3 (en) 2004-10-14

Family

ID=31994180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028931 WO2004024939A2 (en) 2002-09-13 2003-09-12 Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof

Country Status (2)

Country Link
AU (1) AU2003278814A1 (en)
WO (1) WO2004024939A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529154C (en) 2003-06-20 2013-05-07 Galderma Research & Development, S.N.C. Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
BRPI0511099A (en) * 2004-05-14 2007-12-26 Irm Llc compounds and compositions as modulators of ppar
DK1852433T3 (en) 2004-10-29 2012-01-30 Zeria Pharm Co Ltd Carbazole derivatives, solvates thereof or pharmaceutically acceptable salt thereof
WO2006053791A2 (en) * 2004-11-19 2006-05-26 Galderma Research & Development Compounds that modulate ppary type receptors, and use thereof in cosmetic or pharmaceutical compositions
FR2878247B1 (en) * 2004-11-19 2008-10-03 Galderma Res & Dev NOVEL MODULATING COMPOUNDS OF PPARY RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
TW200811164A (en) * 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
US8044236B2 (en) 2006-10-12 2011-10-25 Institute Of Medicinal Molecular Design, Inc. Carboxilic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
RU2010145916A (en) * 2008-04-11 2012-05-20 Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp) PAI-1 INHIBITOR
JP5746864B2 (en) 2008-11-19 2015-07-08 ポーラ化成工業株式会社 Wrinkle improving agent
US8987514B2 (en) 2009-02-04 2015-03-24 President And Fellows Of Harvard College Compositions and methods for labeling and imaging phospholipids
KR20220162116A (en) * 2021-05-25 2022-12-07 주식회사 자이메디 Novel compounds inhibiting the binding between AIMP2-DX2 and KRAS and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 16, 2002, pages 2141 - 2144 *
DATABASE CAPLUS [online] BING ET AL: "N-(arylacetyl)-biphenylalanines as Potent VLA-4 antagonists", Database accession no. 2002:543694 *

Also Published As

Publication number Publication date
WO2004024939A2 (en) 2004-03-25
AU2003278814A1 (en) 2004-04-30
AU2003278814A8 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
WO2004024939A3 (en) Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
Ventola Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants
Jacques et al. Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs
Fraeman et al. Incidence of new-onset hypertension in cancer patients: a retrospective cohort study
Girnun et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin
CN107417572A (en) Benzyl phenylate analog derivative and its preparation method and pharmaceutical composition and purposes
Mitra et al. Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect
Cabebe et al. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
CN1176598A (en) Method and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
NO20065048L (en) Contrast agents for myocardial perfusion imaging.
Ochoa et al. Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
Fang et al. Targeted protein degrader development for cancer: advances, challenges, and opportunities
Foral et al. Oxycodone accumulation in a hemodialysis patient
Savarino et al. Ilaprazole for the treatment of gastro-esophageal reflux
Recio-Boiles et al. Gallbladder cancer
Chen et al. Predicting the effects of different triazole antifungal agents on the pharmacokinetics of tamoxifen
Olmo et al. Acute opioid withdrawal syndrome from naloxone/naloxegol interaction
Padda et al. Lenvatinib
Fujiwara et al. FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies
Hwang et al. Co-administration of vonoprazan, not tegoprazan, affects the pharmacokinetics of atorvastatin in healthy male subjects
Böhm et al. Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib
JP2005525397A5 (en)
JP2004521140A5 (en)
Patel et al. Formulation and evaluation of bilayer tablet by using melt granulation technique for treatment of diabetes mellitus
Lee et al. Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP